| Ticker: ONXX | 3031 Research Drive | |
| Exchange: NASDAQ-National Market | Richmond, California 94806 | |
| Industry: Manufacturing | (510) 222-9700 |
| Type of Shares: | Common Shares | Filing Date: | 4/15/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 5/9/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $30,000,000 | Selling: | $0.48 | |
| Expenses: | $900,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,067,428 |
| Manager | Tier | Phone |
| Montgomery Securities | Lead Manager | 4156272220 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $6.95 | $1.97 | $1.36 | Assets: | $14.33 |
| Net Income: | -$8.43 | -$2.29 | -$2.33 | Liabilities: | $2.92 |
| EPS: | -$1.29 | -$0.35 | Equity: | $11.42 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the discovery and development of novel therapeutics based upon the genetics of human disease, primarily cancer. The Company's goal is to capitalize on the discoveries of the past decade that have established cancer as a genetic-based disease. When certain genes are ,mutated, cells grow and proliferate unchecked and become resistant to internal mechanisms that would normally cause their death. The Company's drug discovery and development programs focus on innovative therapies which target the most frequent mutations causing cancer. Cancer is the second largest killer in the United States, accounting for over 22% of all deaths. The direct cost of treating cancer patients was estimated at $35 billion in 1995, with cancer drug costs totaling $3.0 billion. Of the estimated 1.3 million U.S. patients who are expected to be diagnosed with cancer in 1996, 780,000 or 60% are projected to die within 5 years. |
| Use of Proceeds |
| Proceeds from the offering will be used for research and development; capital expenditures; which may include a pilot scale manufacturing facility; and working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.